3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
11
Other hematologic neoplasm
8
Genitourinary
5
Thoracic
3
Plasma cell
3
Myeloid
3
Breast
3
Gynecologic
2
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Cisplatin
136
Cetuximab
101
pembrolizumab
83
Radiotherapy
62
Carboplatin
57
Radiotherapy, Intensity-Modulated
54
Fluorouracil
47
Docetaxel
47
Nivolumab
44
Paclitaxel
37
Radiation
21
Erlotinib Hydrochloride
19
durvalumab
18
Platinum
15
Ipilimumab
14
Gemcitabine
13
lenvatinib
12
Drug Therapy
12
Bevacizumab
12
Albumin-Bound Paclitaxel
12
vandetanib
11
Pemetrexed
11
Magnetic Resonance Spectroscopy
11
1,2-diaminocyclohexaneplatinum II citrate
11
Radiosurgery
10
Everolimus
10
tremelimumab
9
epacadostat
9
Surgical Procedures, Operative
9
Sorafenib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Diphenhydramine
×
Head & Neck
×
Clear all
NCT03107182
2025-05-06
OPTIMA-II
University of Chicago
Phase 2
Completed
72 enrolled
14 charts